Navigation Links
Juventas Therapeutics Demonstrates JVS-100 Delivery to Patients with Heart Failure is Safe and Provides Clinical Benefit
Date:5/24/2011

CLEVELAND, May 24, 2011 /PRNewswire/ -- Juventas Therapeutics is a privately-held, clinical-stage company developing novel regenerative therapies for treatment of cardiovascular disease.  The Company's lead product, JVS-100, encodes Stromal cell-Derived Factor 1 (SDF-1) which has been shown to repair damaged tissue through recruitment of circulating stem cells to the site of injury, prevention of ongoing cell death and restoration of blood flow.  Juventas recently presented the results from its Phase I heart failure trial at the 14th Annual Meeting of the American Society of Gene and Cell Therapy.

The 17-person, open-label, dose-escalation study targeted New York Heart Association (NYHA) class III heart failure patients. Class III patients represent approximately a quarter of the 6 million heart failure patients in the United States and account for half of all heart failure hospital admissions.

"We wanted to target truly sick patients for whom there are currently no real therapeutic options," states Marc Penn, M.D., Ph.D., scientific founder and Chief Medical Officer for Juventas.  "These patients tend to have a rapidly deteriorating quality of life and the potential to provide clinical benefit is meaningful."

The clinical trial met its safety endpoints and JVS-100 was well-tolerated by all patients at all doses tested.  At four months post-treatment, patients in the targeted therapeutic dose range, are showing clinically-relevant and statistically-significant median improvements of 36 meters for 6 minute walk distance (6MWD) and 22 points in the Minnesota Living with Heart Failure Questionnaire (MLHFQ).  Nearly half of the patients improved a full NYHA heart class and, importantly, no patients worsened in heart class. Echocardiographs demonstrated that the patients' cardiac function stabilized with dose-dependent trends toward improvement in left ventricular end systolic volume (LVESV) and left ventricular ejection fraction (LVEF).

"While the focus of the trial was safety, it is encouraging to see such robust clinical benefit in the treated patients," states Douglas Losordo, M.D., principal investigator for the trial and Director of the Feinberg Cardiovascular Research Institute at the Northwestern University School of Medicine.  "These are exciting results for the cardiovascular regenerative medicine field."

Patients in the trial were also enrolled at Cardiology, P.C. (Birmingham, AL) , Rush University Medical Center (Chicago, IL), and Columbia University Medical Center(New York, NY).

"We're very pleased with the outcome of this study, which builds on more than ten years of research surrounding SDF-1, its role in stem cell homing and tissue repair," indicates Rahul Aras, Ph.D., President & Chief Executive Officer for Juventas.  "We believe JVS-100 provides a clinically attractive means through which to provide regenerative therapy without the complexity often associated with cell therapy.  It has the potential to simplify the treatment paradigm for both the physician and patient."

About Juventas Therapeutics

Juventas Therapeutics, headquartered in Cleveland, OH, is a privately-held clinical-stage biotechnology company developing a pipeline of regenerative therapies to treat life–threatening diseases. Founded in 2007 with an exclusive license from the Cleveland Clinic, Juventas has transitioned its therapeutic platform from concept to initiation of mid-stage clinical trials.  Investors include Triathlon Medical Venture Partners, Early Stage Partners, Fletcher Spaght Ventures, Reservoir Venture Partners, North Coast Angel Fund, X Gen Ltd., JumpStart Inc., and Blue Chip Venture Co. The company has received non-dilutive grant support through the Ohio Third Frontier funded Cleveland Clinic Ohio BioValidation Fund, Global Cardiovascular Innovation Center and Center for Stem Cell & Regenerative Medicine.

About JVS-100

 The company's lead product, JVS-100 encodes Stromal–cell Derived Factor 1 (SDF–1).  SDF-1 promotes tissue repair through recruitment of endogenous stem cells to the damaged organ, promotion of new blood vessel formation and prevention of ongoing cell death.  The SDF-1 repair pathway is well-conserved in a broad range of end organ systems, including the heart, vasculature, dermis, kidney, and eye.  JVS-100 is currently being clinically evaluated for treatment of heart failure and late stage peripheral vascular disease and has been shown to protect and repair tissue following organ–damage in a broad range of pre–clinical disease models. 

Website: www.juventasinc.com


'/>"/>
SOURCE Juventas Therapeutics, Inc.
Copyright©2010 PR Newswire.
All rights reserved

Related biology technology :

1. Juventas Therapeutics Initiating Phase II Clinical Trial of JVS-100 for Treatment of Critical Limb Ischemia
2. Northwest Biotherapeutics to Present at American Society of Cell and Gene Therapy
3. Northwest Biotherapeutics and the Fraunhofer Institute for Cell Therapy and Immunology are Partnering for Clinical Trials and Compassionate Use Cases in Europe
4. Nile Therapeutics to Transition to OTCQB Marketplace
5. Halozyme Therapeutics Reports First Quarter 2011 Financial Results
6. InVivo Therapeutics and The Miami Project to Cure Paralysis Form Strategic Research Collaboration to Develop Novel Treatments for Spinal Cord Injuries
7. Talecris Biotherapeutics Announces Results of Annual Stockholders Meeting
8. Silence Therapeutics Issued Japanese Patent Covering its Core RNA Interference (RNAi) Technology
9. Cell Therapeutics Retires 7.5% Convertible Senior Notes
10. Talecris Biotherapeutics Announces First Quarter 2011 Results
11. Nektar Therapeutics Reports First Quarter 2011 Financial Results
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:3/27/2017)... March 27, 2017  The global market for ... according to a new report from Kalorama Information.  ... is performed to evaluate disease progression, monitor drug ... other reasons.  The healthcare market research firm,s report, ... provides an overview of the medical laboratory industry ...
(Date:3/27/2017)... , March 27, 2017  Trovagene, Inc. (NASDAQ: ... its Chief Executive Officer, Bill Welch , will ... 4, 2017 at 9:00 AM EDT at the Essex ...  Bill Welch, and Chief Scientific Officer, Mark Erlander ... investors during the conference.   The presentation will ...
(Date:3/24/2017)... Mar. 24, 2017 Research and Markets has ... Research - Global Strategic Business Report" report to their offering. ... This report ... in US$ Million. Annual estimates and forecasts are provided for the ... primary and secondary research. The report profiles 25 ...
(Date:3/23/2017)... ... March 23, 2017 , ... AxioMed president, Jake Lubinski, describes ... characteristics when deformed, which is identical to how the human discs work to ... and return to its natural state along a hysteresis curve, exactly like a ...
Breaking Biology Technology:
(Date:3/22/2017)... , March 21, 2017 Vigilant ... company serving law enforcement agencies, announced today the appointment ... as director of public safety business development. ... law enforcement experience, including a focus on the aviation ... his most recent position, Mr. Sheridan served as the ...
(Date:3/9/2017)... , Australia , March 9, ... study data at the prestigious World Lung Imaging Workshop ... Andreas Fouras , was invited to deliver the ... pulmonary medicine. This globally recognised event brings together leaders ... share the latest developments in lung imaging. ...
(Date:3/2/2017)... YORK , March 2, 2017 Summary ... better understand Perrigo and its partnering interests and activities since ... ... Partnering Deals and Alliance since 2010 report provides an in-depth ... leading life sciences companies. On demand company reports ...
Breaking Biology News(10 mins):